Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives $12.38 Average Target Price from Analysts

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) has earned an average recommendation of “Buy” from the five analysts that are currently covering the company, Marketbeat.com reports. Four investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $12.38.

A number of research firms have weighed in on CRVS. Oppenheimer upped their price objective on shares of Corvus Pharmaceuticals from $8.00 to $14.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Mizuho upgraded Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 22nd. StockNews.com lowered Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, October 31st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price on shares of Corvus Pharmaceuticals in a research report on Tuesday, January 14th.

Corvus Pharmaceuticals Stock Performance

NASDAQ CRVS opened at $5.08 on Monday. The stock has a market cap of $326.44 million, a P/E ratio of -5.46 and a beta of 1.07. The company’s fifty day simple moving average is $6.40 and its 200-day simple moving average is $5.74. Corvus Pharmaceuticals has a 52 week low of $1.30 and a 52 week high of $10.00.

Institutional Investors Weigh In On Corvus Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. Cubist Systematic Strategies LLC acquired a new position in Corvus Pharmaceuticals during the 2nd quarter valued at approximately $44,000. Nwam LLC acquired a new position in shares of Corvus Pharmaceuticals during the third quarter valued at $53,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Corvus Pharmaceuticals during the fourth quarter worth about $73,000. XTX Topco Ltd acquired a new stake in shares of Corvus Pharmaceuticals in the 3rd quarter worth about $74,000. Finally, Virtu Financial LLC bought a new stake in Corvus Pharmaceuticals in the 3rd quarter valued at about $83,000. 46.64% of the stock is currently owned by institutional investors.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.